EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions

Jie Shao iD, Marion Vetter, An Vermeulen iD, Brian G Feagan iD, Bruce E Sands iD, Julian Panés iD, Zhenhua Xu iD

Clinical Pharmacology & Therapeutics · 2024-06 · 115 (6) · 1418-1427

DOI: 10.1002/cpt.3235 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 15.03.2024. Verfasst von Jie Shao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Drug Interactions. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Janssen Research & Development, LLC, Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A proof‐of‐concept study with the combination of guselkumab and golimumab in patients with ulcerative colitis (UC) has shown that the combination therapy resulted in greater efficacy than the individual monotherapies. The current analysis evaluated the pharmacokinetics (PK) and immunogenicity of guselkumab and golimumab in both the combination therapy and individual monotherapies. Blood samples were collected to evaluate serum concentrations and immunogenicity of guselkumab and golimumab. Population PK (PopPK) models were developed to assess the effects of combination therapy and other potential covariates on the PK of guselkumab and golimumab. The guselkumab PK was comparable between monotherapy and combination therapy, whereas golimumab concentrations were slightly higher with combination therapy. The anti‐guselkumab antibody incidence was low with both monotherapy and combination therapy, and guselkumab immunogenicity did not impact the clearance. Conversely, the anti‐golimumab antibody incidence with combination therapy was lower than that for monotherapy. PopPK analysis suggested that the slightly higher golimumab concentrations with combination therapy were partially due to lower immunogenicity and thus lower clearance with combination therapy. C‐reactive protein (CRP) was also a significant covariate on golimumab clearance. The greater improvement of inflammation with combination therapy, as shown by reductions in CRP, may have also contributed to the higher golimumab concentrations. Combination therapy slightly decreased the clearance of golimumab, but not guselkumab clearance, in patients with UC. Lower immunogenicity and greater improvement of inflammation with combination therapy were potential mechanisms for slightly increased golimumab concentrations with combination therapy as compared with golimumab monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedColitis, UlcerativeDrug InteractionsDrug Therapy, CombinationAdultFemaleHumansMaleMiddle AgedGastrointestinal AgentsModels, BiologicalProof of Concept StudySeverity of Illness IndexTreatment Outcome

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedGastrointestinal Agentsgolimumabguselkumab

Autor:innen und Institutionen

  • Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Clinical Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
  • Western University, London, Ontario, Canada.
  • Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Gastroenterology, Hospital Clinic of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain.

ORCID-Profile: Jie Shao, An Vermeulen, Brian G Feagan, Bruce E Sands, Julian Panés, Zhenhua Xu

Förderung

  • Janssen Research & Development, LLC
  • Janssen Research and Development

Zitieren

APA

Shao, J., Vetter, M., Vermeulen, A., Feagan, B. G., Sands, B. E., Panés, J., & Xu, Z. (2024). Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions. Clinical Pharmacology & Therapeutics, 115(6), 1418-1427. https://doi.org/10.1002/cpt.3235

Vancouver

Shao J, Vetter M, Vermeulen A, Feagan BG, Sands BE, Panés J, et al. Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions. Clinical Pharmacology & Therapeutics. 2024;115(6):1418-1427. doi:10.1002/cpt.3235

BibTeX
@article{Shao2024,
  author = {Shao, Jie and Vetter, Marion and Vermeulen, An and Feagan, Brian G and Sands, Bruce E and Panés, Julian and Xu, Zhenhua},
  title = {Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {115},
  number = {6},
  pages = {1418--1427},
  doi = {10.1002/cpt.3235}
}
Kostenlos starten →